Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03651505 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

X-linked Hypophosphatemia Disease Monitoring Program

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 77 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 38 sitesv77
  2. 3 versions Re-verified since Oct 29, 2025, no change to tracked fieldsv74-v76
  3. Enrollment target: 780 to 782 Study sites: 39 to 38v73 Show 1 more changeShow less
    • Study sites: 39 to 38
  4. Re-verified, no change to tracked fieldsv72
  5. Study sites revised (39)v71 See this version in full on ClinicalTrials.gov ↗
Show 43 earlier versionsHide 43 earlier versions
  1. 9 versions Re-verified since Mar 6, 2023, no change to tracked fieldsv62-v70
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 39 of 39 sitesv61 Show 1 more changeShow less
    • Site details revised at 39 of 39 sites
  3. Re-verified, no change to tracked fieldsv60
  4. Study sites: 38 to 39v59
  5. 3 versions Re-verified since Jul 29, 2022, no change to tracked fieldsv56-v58
  6. Enrollment target: 800 to 780v55
  7. Site details revised at 1 of 38 sitesv54
  8. Primary and study completion dates: Jul 2028 to Dec 2032v53
  9. Site details revised at 24 of 38 sitesv52
  10. 2 versions Re-verified since Feb 4, 2022, no change to tracked fieldsv50-v51
  11. Study sites: 37 to 38v49
  12. Study sites: 35 to 37v48
  13. 5 versions Re-verified since Jul 30, 2021, no change to tracked fieldsv43-v47
  14. Site details revised at 1 of 35 sitesv42
  15. Re-verified, no change to tracked fieldsv41
  16. Study sites: 33 to 35v40
  17. Site details revised at 16 of 33 sitesv39
  18. Re-verified, no change to tracked fieldsv38
  19. Site details revised at 3 of 33 sitesv37
  20. Re-verified, no change to tracked fieldsv36
  21. Enrollment target: 500 to 800 Study sites: 32 to 33v35 Show 1 more changeShow less
    • Study sites: 32 to 33
  22. Re-verified, no change to tracked fieldsv34
  23. Site details revised at 1 of 32 sites Collaborators expanded, about 4 wordsv33 Show 1 more changeShow less
    • Collaborators expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  24. Study sites: 31 to 32v32
  25. Site details revised at 2 of 31 sitesv31
  26. Re-verified, no change to tracked fieldsv30
  27. Enrollment target: 650 to 500 Study sites: 33 to 31v29 Show 1 more changeShow less
    • Study sites: 33 to 31
  28. Re-verified, no change to tracked fieldsv28
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.
Trial Details
NCT Number NCT03651505
Lead Sponsor Ultragenyx Pharmaceutical Inc
Collaborators: Kyowa Kirin Co., Ltd.
Conditions X-linked Hypophosphatemia, Hypophosphatemic Rickets
Enrollment 782 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov